Background
Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a relatively frequent complication in critically ill patients and is responsible for significant comorbidity and mortality levels. For five decades, multiple studies have aimed to determine the mechanisms of ARDS and reduce mortality rates. However, only lung-protective ventilation strategies with low tidal volume ventilation have been shown to reduce mortality in ARDS patients. To date, effective pharmacological therapies have not been identified for ARDS [
1].
Mechanical ventilation is a life-saving tool for respiratory failure patients, but the development of ventilator-induced lung injury (VILI) is still a major problem in mechanically ventilated patients. In particular, high ventilation pressures and high tidal volumes to maintain proper oxygenation and CO
2 elimination can cause lung damage and impair gas exchange. VILI arises from constant cyclical stretching and is characterized by alveolar wall disruption, edema formation, immune cell influx, proinflammatory cytokine release, and the excessive reactive oxygen species (ROS) production [
2]. Despite advances in critical care medicine, the mortality and morbidity rates of VILI patients are still high. There is an urgent need to develop novel therapies for VILI.
Melatonin (N-acetyl-5-methoxytryptamine) is synthesized by the pineal gland in mammals and also by other nonendocrine organs, such as the skin, gut, and immune system. It has multiple properties, including antiapoptotic, antioxidative, and anti-inflammatory effects. Melatonin exerts its physiological effects via receptor-dependent and receptor-independent signaling cascades [
3,
4]. The role of melatonin receptors in organ protection has been investigated. The activation of melatonin receptors has been reported to protect against myocardial ischemia/reperfusion injury and cyclosporine A cardiotoxicity [
5,
6]. In addition, melatonin also exerts antiapoptotic effects via melatonin receptor interactions [
4]. Furthermore, melatonin receptors mediate improvements in survival after polymicrobial sepsis in rats and mice [
7].
IL-10 is an anti-inflammatory cytokine with strong effects on numerous cell types, particularly circulating and resident immune cells and epithelial cells. Previous studies have shown that lung cells subjected to stretching have reduced IL-10 production [
8]. In a model of VILI, IL-10 inhalation reduced the concentrations of macrophage inflammatory protein-2 and IL-1β in bronchoalveolar lavage fluid (BALF) and plasma [
2]. In addition, IL-10 is produced by Th2 cells.
There is increasing evidence that melatonin modulates immune responses and exhibits marked modulatory functions in effector T cells [
9]. Investigations have revealed that melatonin enhances the secretion of IL-4 and IL-10, acting in the Th2-like immune response [
9]. In addition, the regulation of T cell functions by melatonin occurs via melatonin receptors because the effect of melatonin on the activation of T cell functions is suppressed by luzindole (a melatonin receptor antagonist) treatment [
9].
Ramelteon is a potent and highly selective agonist of the high-affinity melatonin receptor 1 (MT1) and MT2 receptors and has antioxidative and anti-inflammatory effects [
10‐
12]. However, the role of melatonin receptor agonist in experimental VILI has not yet been investigated. Thus, the purpose of this study was to determine whether ramelteon provided protection in a rat model of VILI and its protective mechanism was via regulating IL-10 production.
Discussion
This study demonstrated that VILI significantly increased lung edema, neutrophil infiltration, inflammatory cytokine production, oxidative stress, apoptosis, IκB-α degradation, nuclear translocation of NF-κB, and tissue injury. These effects were significantly attenuated by treatment with melatonin or ramelteon. However, the protective effect of melatonin or ramelteon was blocked by the administration of luzindole or an anti-IL-10 antibody. These findings indicate that melatonin receptors mediate the protective effects against VILI and that the underlying protective mechanism of ramelteon occurs via the enhancement of IL-10 production.
Oxidative stress contributes significantly to the pathogenesis of ALI/ARDS [
19]. Melatonin is a strong anioxidant that scavenges ROS, decreases MDA levels, and stimulates the synthesis of antioxidant enzymes. The protective effect of melatonin against oxidative stress may occur via the activation of melatonin receptors, which can stimulate the production of a variety of antioxidative enzymes through several signaling pathways [
20,
21]. Nevertheless, recent studies also demonstrate that melatonin can act as a prooxidant under certain conditions [
22]. Generally, the prooxidant effects of melatonin have been reported in vitro cell culture systems and dependent on concentration, cell type, and the duration of the treatment [
22]. The antioxidant capacity of melatonin has been well established both in vitro and in vivo, while its prooxidant property has been observed at the same time [
14,
22‐
25]. The relevance of this finding is unclear, therefore, more studies addressing this issue are necessary.
Our data demonstrate that melatonin and ramelteon treatment suppressed oxidative stress, as reflected by the attenuation of protein carbonylation in lung tissue and serum MDA levels in VILI. In addition, melatonin and ramelteon treatment attenuated the VILI-induced increase in neutrophil infiltration in the lung tissue, as evidenced by the reduced numbers of neutrophils and MPO-positive cells. This attenuation reduced the production of proinflammatory cytokines and free radicals by activated neutrophils. Therefore, the antioxidative and anti-inflammatory effects of melatonin and ramelteon appeared to attenuate lung edema, as shown by the reduced W/D and LW/BW ratios, as well as reduced protein concentration in BALF. However, the antioxidative and anti-inflammatory effects of melatonin and ramelteon were significantly decreased by luzindole treatment. These results demonstrate that melatonin receptors play an important role in the antioxidative and anti-inflammatory effects of melatonin and ramelteon. As previous reports, the antioxidative and anti-inflammatory effects of ramelteon were reversed by the melatonin receptor antagonist luzindole [
12,
26], we suggest that ramelteon mediates its protective effect of VILI mostly through the melatonin receptor.
ROS have been shown to promote the apoptotic response in various physiological processes [
27]. Epithelial cell apoptosis also occurs in ALI/ARDS, and can potentially be limited by blocking apoptosis pathways [
19,
27]. Caspase-3 is a key player in the execution phase of apoptosis, and PARP is cleaved by caspase-3 during the process. Reducing the cleavage of PARP can prevent ALI development [
27]. Bcl-2 can protect cells against apoptosis, and evidence suggests that its overexpression can inhibit apoptosis in response to a variety of stimuli. This inhibition of apoptosis involves the modulation of caspase-3 and PARP degradation [
28].
Hsp70 is an important type of stress-induced protein and is also an antiapoptotic protein that protects tissues from cytotoxicity induced by oxidative stress and other stress conditions [
29]. Previous studies have implied that ALI leads to the downregulation of Hsp70 expression in the lungs [
18]. Another study demonstrated that enhanced Hsp70 expression attenuates apoptosis in ALI [
30]. Moreover, HSP70 overexpression inhibits caspase-3 activation and PARP cleavage [
31,
32].
Melatonin has been shown to inhibit apoptosis by decreasing caspase-3 and increasing Bcl-2 expression in injured lungs [
14]. Additionally, melatonin enhances the expression of heat shock proteins, such as Hsp70, preventing renal damage and arrhythmogenic myocardial remodeling during unilateral ureteral obstruction [
29]. The antiapoptotic effect of melatonin is mediated by melatonin receptors, and luzindole abolishes their activity [
4]. A vast amount of evidence has demonstrated that the antiapoptotic effects of melatonin involve the membrane melatonin receptors. Sinha et al. showed that the activation of caspase-3 in hypoxic-ischemic injury occurs in parallel to the downregulation of melatonin receptor expression. The activation of caspase-3 is reduced by the administration of melatonin, while luzindole effectively blocks the melatonin-induced inhibition of caspase-3 activation [
33,
34].
In addition, melatonin activates Bcl-2 in the mitochondria, which antagonizes bax and thereby inhibits apoptosis via interactions with melatonin receptors [
35]. Furthermore, the activation of melatonin receptors increases the expression of Hsp70 [
36]. As shown in the present study, the antiapoptotic and antioxidant effects of melatonin seem to be dependent on melatonin receptors. Similar to the effect of melatonin, the present results show that ramelteon has the ability to modulate ROS production and Bcl-2, caspase-3, PARP, and Hsp70 expression, which results in the attenuation of VILI.
Activation of the NF-κB signaling pathway is central to the pathophysiology of the inflammatory response, and NF-κB can be activated by oxidative stress, bacterial endotoxins, and cytokines. The functional importance of NF-κB in inflammation is based on its ability to regulate the promoters of multiple inflammatory genes, including TNF-α, IL-1β, IL-6, and iNOS [
37]. The inappropriate activation of NF-κB is implicated in the pathogenesis of ALI/ARDS [
19]. Moniruzzaman et al. demonstrated that melatonin regulates the activation of NF-κB through the induction of the expression of its receptor protein [
38]. Moreover, the expression and activity of iNOS are significantly upregulated by high tidal ventilation and correlate with lung edema in VILI. iNOS-deficient mice are protected from pulmonary edema in response to mechanical ventilation with high tidal ventilation [
39].
Jung et al. demonstrated that melatonin treatment attenuates the protein expression of iNOS in rats with dimethylnitrosamine-induced liver injury [
40]. Hsu et al. demonstrated that melatonin treatment attenuates iNOS expression, which is mediated by melatonin receptors, as luzindole treatment blocks the melatonin-induced decrease in iNOS expression [
41]. The present study results show that melatonin or ramelteon treatment inhibits the expression of NF-κB and iNOS. The effects of melatonin or ramelteon may be mediated by binding to melatonin receptors since luzindole blocks the decreases in expression.
Proinflammatory cytokines play a pivotal role in ALI/ARDS [
42]. For example, the elevation of cytokines and chemokines such as TNF-
α, IL-1β, IL-6, and IL-8 is a feature that is common in ALI/ARDS [
42]. In a previous report, melatonin was found to inhibit LPS-stimulated TNF-α, IL-1β, IL-6, IL-8, and iNOS production through a mechanism involving the attenuation of NF-κB activation. The effects of melatonin could be at least partially mediated by binding to melatonin receptors because luzindole attenuates melatonin-induced decreases in the production of proinflammatory cytokines [
43]. Consistent with previous reports, we found that melatonin or ramelteon treatment decreased the levels of proinflammatory cytokines in VILI via melatonin receptors.
STAT3 is considered an important proinflammatory regulator. The activation of STAT3 may be a common signaling mechanism that contributes to the pathogenesis of ALI. The suppression of STAT3 activity has been shown to attenuate LPS-induced ALI [
44]. STAT target genes contribute to the production of cytokines, chemokines, adhesion molecules, and other inflammatory mediators. IL-6 is a well-described STAT3 activator [
45]. In the current study, the activation and inhibition of STAT3 phosphorylation occurred in parallel with IL-6 production. Furthermore, we also found that melatonin or ramelteon treatment inhibited IL-6 production and consequently decreased STAT3 phosphorylation, which was also mediated via melatonin receptors.
IL-10 is an anti-inflammatory cytokine in the context of both acute and chronic inflammation [
46]. IL-10 has multiple protective effects and is known to alleviate ALI by reducing the activity of MPO, attenuating the production of TNF-
α, IL-1β, IL-6, and MIP-2, suppressing NF-κB activation, and decreasing iNOS expression [
2,
47,
48]. In an in vivo experiment, Hoegl et al. showed that the inhalation of IL-10 reduced the concentrations of MIP-2 and IL-1β in BALF and plasma induced by high-pressure ventilation [
2]. Additionally, IL-10 increased the survival of animals [
2]. IL-10 also inhibited ROS production, which in turn inhibited IκB-α degradation, decreased NF-κB activity, and hence decreased the expression of inflammatory cytokines [
49]. Furthermore, IL-10 has also been shown to suppress the expression of iNOS and reduce the production of nitric oxide in various types of cells [
50].
Lee et al. showed that IL-10 protects cultured rat type II epithelial cells from injury induced by mechanical stretching by decreasing apoptosis [
51]. IL-10 has antiapoptotic effects since it has been shown to inhibit TNF-α-induced caspase activity and restore the impaired bax/bcl-2 ratio in articular chondrocytes [
52]. Moreover, the Hsp70-driven downregulation of proinflammatory cytokine production is dependent on IL-10 [
53,
54]. Wu et al. showed that the IL-10 expression induced by melatonin can improve ALI induced by heatstroke [
55].
Melatonin receptors are tightly associated with the signal transduction of melatonin [
56,
57]. In this study, we found that the protective effects of melatonin exerted against VILI are mediated by melatonin receptors. Melatonin- or ramelteon-induced IL-10 expression in VILI is mediated by melatonin receptors since luzindole treatment abrogates the effect. When we administered an anti-IL-10 antibody, the protective effects of melatonin and ramelteon against VILI were abrogated, resulting in increasing lung edema, TNF-α, IL-1β and IL-6 levels in BALF, NF-κB expression, and apoptosis in lung tissue, which indicated that melatonin receptors upregulated IL-10 production and improved VILI. However, further study is warranted to clarify how melatonin receptor agonist can enhance IL-10 production.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.